Cargando…
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
OBJECTIVE: To compare effects of an initial dose of calcitonin gene‐related peptide (CGRP) monoclonal antibody (mAb) antagonists on gastrointestinal (GI) motility in patients with migraine and to explore if the mechanistic difference contributes to GI adverse events (AEs). BACKGROUND: Different freq...
Autores principales: | Kudrow, David, Nguyen, Linda, Semler, Jack, Stroud, Chad, Samaan, Karen, Hoban, Deirdre B., Wietecha, Linda, Hsu, Hai‐An, Pearlman, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826055/ https://www.ncbi.nlm.nih.gov/pubmed/36111429 http://dx.doi.org/10.1111/head.14390 |
Ejemplares similares
-
Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021) -
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020) -
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019) -
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021) -
Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)